

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

May 2024

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white wavy lines on a grey background.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 May 2024	3
Changes to General Rules.....	7
Section H changes to Part II	8
Index.....	22

Summary of decisions

EFFECTIVE 1 MAY 2024

- Ambrisentan (Ambrisentan Viatrix) tab 5 mg and 10 mg – amended restriction criteria
- Amino acid formula (without lysine) (GA Express 15) 30 sachets – to be delisted from 1 May 2024
- Amino acid formula (e.g. Neocate SYNEO (Unflavoured) and e.g. Neocate Junior (Unflavoured)), 400 g can – any brand to be delisted from 1 May 2024
- Amino acid formula (Neocate SYNEO (Unflavoured) and Neocate Junior (Unflavoured)), 400 g – new listing
- Amino acid formula (Neocate Gold (Unflavoured) and Neocate Junior Vanilla), 400 g – price increase
- Amino acid oral feed 0.8 kcal/ml (e.g. Elemental 028 Extra) 250 ml carton – any brand to be delisted from 1 May 2024
- Amino acid oral feed 0.8 kcal/ml (Elemental 028 Extra (Grapefruit, Summer Fruits and Pineapple and Orange) 18 carton – new listing
- Carbohydrate and fat supplement (Duocal Super Soluble Duocal Powder) 400 g – new listing
- Carbohydrate and fat supplement (e.g. Super Soluble Duocal) 400 g can – any brand to be delisted from 1 May 2024
- Carbohydrate supplement (e.g. Polycal), 400 g can – any brand to be delisted 1 May 2024
- Carbohydrate supplement (Polycal), 400 g – new listing
- Carob bean gum with maize starch and maltodextrin (Aptamil Feed Thickener) 380 g – new listing
- Carob bean gum with maize starch and maltodextrin (e.g. Feed Thickener Karicare Aptamil) 380 g can – any brand to be delisted from 1 May 2024
- Cefuroxime (Cefuroxime-AFT) inj 750 mg and 1.5 g vial – delayed delist date
- Cefuroxime (Cefuroxime Devatis) inj 750 mg and 1.5 g vial – delayed PSS date
- Ciprofloxacin (Ciprofloxacin – Torrent) tab 500 mg – new listing
- Dolutegravir with lamivudine (Dovato) tab 50 mg with lamivudine 300 mg – new listing
- Dulaglutide (Trulicity) inj 1.5 mg per 0.5 ml prefilled pen – amended restriction criteria
- Enteral feed (Nutrison Energy) 1,000 ml – price increase
- Enteral feed 1 kcal/ml (Nutrison Multi Fibre), 1000 ml – new listing
- Enteral feed 1 kcal/ml (Nutrison RTH) 1,000 ml – new listing
- Enteral feed 1 kcal/ml (e.g. Nutrison Multi Fibre and e.g. Nutrison Low Sodium; NutrisonStdRT), 1,000 ml bottle – any brand to be delisted from 1 May 2024

Summary of decisions – effective 1 May 2024 (continued)

- Enteral feed 1.5 kcal/ml (e.g. Nutrison Energy Multi Fibre), 1,000 ml bottle – any brand to be delisted from 1 May 2024
 - Enteral feed 1.5 kcal/ml (Nutrison Energy Multi Fibre) 1,000 ml – new listing
 - Enteral feed 2 kcal/ml (Nutrison Concentrated) 500 ml – price increase
 - Enteral feed with fibre 0.83 kcal/ml (Nutrison 800 Complete Multi Fibre) 1,000 ml – price increase
 - Enteral liquid peptide formula (Nutrini Peptisorb Energy), 500 ml – price increase
 - Erlotinib (Alchemy) tab 100 mg and 150 mg – price decrease and addition of PSS
 - Extensively hydrolysed formula (e.g. Pepti-Junior) 450 g can – any brand to be delisted from 1 May 2024
 - Extensively hydrolysed formula (Pepti-Junior) 450 g – new listing
 - Extensively hydrolysed formula (Allerpro Syneo 1 and Allerpro Syneo 2), 900 g – price increase
 - Fat-modified feed (e.g. Monogen) 400 g can – any brand to be delisted from 1 May 2024
 - Fat-modified feed (Monogen) 400 g – new listing
 - Flecainide acetate (Tambocor) inj 10 mg per ml, 15 ml ampoule – price increase
 - Fluticasone furoate with umeclidinium and vilanterol (Trelegy Ellipta) powder for inhalation fluticasone furoate 100 mcg with umeclidinium 62.5 mcg and vilanterol 25 mcg – new listing
 - Glycerol trioleate (GTO Oil) 500 ml – new listing
 - Hepatic oral feed (Heparon Junior) 400 g – price increase
 - High fat formula (Ketocal 4:1 (Unflavoured), Ketocal 4:1 (Vanilla) and Ketocal 3:1 (Unflavoured)) 300 g – price increase
 - High protein enteral feed 1.25 kcal/ml (e.g. Nutrison Protein Plus) 1,000 ml bottle – any brand to be delisted from 1 May 2024
 - High protein enteral feed 1.25 kcal/ml (Nutrison Protein Plus) 1,000 ml – new listing
 - High protein enteral feed 1.26 kcal/ml (Nutrison Protein Intense) 500 ml – price increase
 - High protein enteral feed 1.28 kcal/ml (e.g. Nutrison Protein Plus Multi Fibre) 1,000 ml bottle – any brand to be delisted from 1 May 2024
 - High protein enteral feed 1.28 kcal/ml (Nutrison Protein Plus Multi Fibre) 1,000 ml – new listing
 - Human milk fortifier (Human Milk Fortifier) 50 sachets – new listing
 - Human milk fortifier (e.g. FM 85, e.g. S26 Human Milk Fortifier and e.g. Nutricia Breast Milk Fortifier) – amended chemical name
 - Human milk fortifier (e.g. S26 Human Milk Fortifier and e.g. Nutricia Breast Milk Fortifier) – any brand to be delisted from 1 May 2024
-

Summary of decisions – effective 1 May 2024 (continued)

- Hyoscine hydrobromide (Scopolamine – Mylan) patch 1 mg per 72 hours – new Pharmacode listing
- Liraglutide (Victoza) inj 6 mg per ml, 3 ml prefilled pen – amended restriction criteria
- Long-chain triglyceride supplement (e.g. Calogen), 200 ml and 500 ml bottle – any brand to be delisted from 1 May 2024
- Long-chain triglyceride supplement, 200 ml (Calogen (Neutral and Strawberry)) and 500 ml (Calogen (Neutral)) – new listing
- Low electrolyte oral feed (e.g. Kindergen) 400 g can – any brand to be delisted from 1 May 2024
- Low electrolyte oral feed (Kindergen) 400 g – new listing
- Low electrolyte oral feed 2 kcal/ml (e.g. Renilon 7.5) 125 ml carton – any brand to be delisted from 1 May 2024
- Low electrolyte oral feed 2 kcal/ml (Renilon 7.5 (apricot and caramel)) 4 carton – new listing
- Low-calcium formula (e.g. Locasol), 400 g can – any brand to be delisted from 1 May 2024
- Low-calcium formula (Locasol) 400 g – new listing
- Low-GI oral feed 1 kcal/ml (e.g. Diasip), 200 ml bottle – any brand to be delisted from 1 July 2024
- Maize starch (e.g. Resource Thicken Up; Nutilis) 300 g can – any brand to be delisted from 1 May 2024
- Maize starch (Nutilis) 300 g – new listing
- Medium-chain triglyceride supplement (e.g. Liquigen), 250 ml bottle – any brand to be delisted 1 May 2024
- Medium-chain triglyceride supplement (Liquigen), 4 bottles – new listing
- Medium-chain triglyceride supplement (e.g. MCT Oil), 500 ml bottle – any brand to be delisted 1 May 2024
- Medium-chain triglyceride supplement (MCT Oil), 500 ml – new listing
- Mepolizumab (Nucala) inj 100 mg prefilled pen and inj 100 mg vial – amended restriction criteria
- Mirtazapine (Noumed) tab 30 mg and 45 mg, 30 tab pack – new listing
- Multivitamins (e.g. Paediatric Seravit) – any brand to be delisted from 1 May 2024
- Multivitamins (Paediatric Seravit), 200 g – new listing
- Niraparib (Zejula) cap 100 mg, 56 and 84 cap pack – new listing
- Oral feed 1.5 kcal/ml (Fortijuce (Apple, Orange and Strawberry)) 200 ml – new listing

Summary of decisions – effective 1 May 2024 (continued)

- Oral feed 1.5 kcal/ml (e.g. Fortijuce), 200 ml bottle – any brand to be delisted from 1 May 2024
- Oral feed 1.5 kcal/ml (e.g. Fortisip and e.g. Fortisip Multi Fibre), 200 ml bottle – any brand to be delisted from 1 July 2024
- Paediatric enteral feed 0.76 kcal/ml (Nutrini Low Energy Multifibre) 500 ml – new Pharmacode listing
- Paediatric enteral feed 0.76 kcal/ml (Nutrini Low Energy Multifibre), 500 ml, Pharmacode 2400421 – to be delisted from 1 May 2024
- Paediatric enteral feed 1 kcal/ml (e.g. Nutrini RTH) 500 ml bottle – any brand to be delisted from 1 May 2024
- Paediatric enteral feed 1 kcal/ml (Nutrini RTH), 500 ml – new listing
- Paediatric enteral feed 1.5 kcal/ml (Nutrini Energy Multi Fibre) 500 ml – price increase
- Paediatric enteral feed 1.5 kcal/ml (e.g. Nutrini Energy RTH) 500 ml bottle – any brand to be delisted from 1 May 2024
- Paediatric enteral feed 1.5 kcal/ml (Nutrini Energy RTH), 500 ml – new listing
- Paediatric oral feed 1 kcal/ml (Fortini (Strawberry and Vanilla)) 200 ml bottle – new listing
- Paediatric oral feed 1 kcal/ml (Fortini Multi Fibre (Unflavoured, Chocolate, Strawberry and Vanilla)) 200 ml bottle – new listing
- Paediatric oral feed 1.5 kcal/ml (e.g. Fortini and e.g. Fortini Multifibre) – any brand to be delisted from 1 May 2024
- Paediatric oral/enteral feed 1kcal/ml (Infatrini) 125 ml – price increase
- Peptide-based enteral feed 1kcal/ml (Nutrison Advanced Peptisorb) 500 ml – new listing
- Povidone-iodine (Riodine) soln 10% – price increase
- Preoperative carbohydrate feed 0.5 kcal/ml (preOp) 200 ml bottle – price increase
- Protein supplement (e.g. Protifar) 225 g can – any brand to be delisted from 1 May 2024
- Protein supplement (Protifar), 225 g – new listing
- Theophylline tab long-acting 250 mg (Nuelin-SR) and oral liq 80 mg per 15 ml (Nuelin) – price increase
- Tocilizumab (Actemra) inj 20 mg per ml, 4 ml vial, 10 ml vial and 20 ml vial – amended restriction criteria
- Trientine (Trientine Waymade) cap 250 mg – new listing and addition of PSS
- Trientine dihydrochloride cap 300 mg – to be delisted from 1 October 2024

Changes to General Rules

Effective 1 May 2024

Editorial amendments

We have changed all Te Whatu Ora references to Health NZ. There are corresponding amendments to the General Rules of the Pharmaceutical Schedule.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 May 2024

ALIMENTARY TRACT AND METABOLISM

11 DULAGLUTIDE – **Restricted: For continuation only** (amended restriction criteria)

Note: Not to be given in combination with a funded SGLT-2 inhibitor or other GLP-1 agonist.

➔ Inj 1.5 mg per 0.5 ml prefilled pen..... 115.23 4 Trulicity

Initiation

Either:

1 For continuation use; or

2 All of the following:

2.1 Patient has type 2 diabetes; and

2.2 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of ALL of the following funded blood glucose lowering agents for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin (see note a)*; and

2.3 Any of the following:

2.3.1 Patient is Māori or any Pacific ethnicity*²; or

2.3.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note b)*²; or

2.3.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*²; or

2.3.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*²; or

2.3.5 Patient has diabetic kidney disease (see note c)*².

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes:

a) Due to the ongoing supply issues with GLP-1 agonists, we strongly urge prescribers to consider initiating patients on other hypoglycaemic agents, provided they are not contraindicated. Please also consider discontinuing GLP-1 agonist treatment where the patient is not receiving clinically meaningful benefit.

b) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease); congestive heart failure or familial hypercholesterolaemia.

c) Diabetic kidney disease defined as: persistent albuminuria (albumin: creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

- 11 LIRAGLUTIDE – **Restricted: For continuation only** (amended restriction criteria)
 Note: Not to be given in combination with a funded SGLT-2 inhibitor or other GLP-1 agonist.
 → Inj 6 mg per ml, 3 ml prefilled pen 383.72 3 Victoza

Initiation

Either:

1 For continuation use; or

2 All of the following:

2.1 Patient has type 2 diabetes; and

2.2 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of ALL of the following funded blood glucose lowering agents for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin (see note a)*; and

2.3 Any of the following:

2.3.1 Patient is Māori or any Pacific ethnicity*; or

2.3.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note b)*; or

2.3.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or

2.3.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or

2.3.5 Patient has diabetic kidney disease (see note c)*.

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

a) Due to the ongoing supply issues with GLP-1 agonists, we strongly urge prescribers to consider initiating patients on other hypoglycaemic agents, provided they are not contraindicated. Please also consider discontinuing GLP-1 agonist treatment where the patient is not receiving clinically meaningful benefit.

b) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.

c) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

22	TRIENTINE (new listing and addition of PSS) → Cap 250 mg – 5% DV Oct-24 to 2025	2,022.00	100	Trientine Waymade
	Initiation All of the following: 1 Patient has confirmed Wilson disease; and 2 Treatment with D-penicillamine has been trialled and discontinued because the person has experienced intolerable side effects or has not received sufficient benefit; and 3 Treatment with zinc has been trialled and discontinued because the person has experienced intolerable side effects or has not received sufficient benefit, or zinc is considered clinically inappropriate as the person has symptomatic liver disease and requires copper chelation.			
22	TRIENTINE DIHYDROCHLORIDE (delisting any brand) Cap 300 mg Note – Trientine dihydrochloride cap 300 mg to be delisted from 1 October 2024			
26	MULTIVITAMINS (new listing) → Powder vitamin A 3200 mcg with vitamin D 100 mcg, vitamin E 54.2 mg, vitamin C 400 mg, vitamin K1 108 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 41 mg, vitamin B6 3.6 mg, folic acid 600 mcg, vitamin B12 9 mcg, biotin 120 mcg, pantothenic acid 24 mg, choline 1250 mg and inositol 700 mg.....	74.88	200 g	Paediatric Seravit
	Initiation Patient has inborn errors of metabolism.			
26	MULTIVITAMINS (delisting any brand) → Powder vitamin A 3200 mcg with vitamin D 100 mcg, vitamin E 54.2 mg, vitamin C 400 mg, vitamin K1 108 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 41 mg, vitamin B6 3.6 mg, folic acid 600 mcg, vitamin B12 9 mcg, biotin 120 mcg, pantothenic acid 24 mg, choline 1250 mg and inositol 700 mg Note – e.g. Paediatric Seravit to be delisted from 1 May 2024			<i>e.g. Paediatric Seravit</i>

CARDIOVASCULAR SYSTEM

45	FLECAINIDE ACETATE († price) Inj 10 mg per ml, 15 ml ampoule	108.16	5	Tambocor
----	---	--------	---	----------

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

- 54 AMBRISENTAN (amended restriction criteria – amended criteria shown only)
- | | | | |
|---|--------|----|----------------------------|
| → Tab 5 mg – 5% DV Dec-23 to 2026 | 200.00 | 30 | Ambrisentan Viatris |
| → Tab 10 mg – 5% DV Dec-23 to 2026 | 200.00 | 30 | Ambrisentan Viatris |
- Initiation – PAH dual therapy
Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist
Limited to 6 months treatment
All of the following:
- 1 Patient has pulmonary arterial hypertension (PAH); and
 - 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
 - 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
 - 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
 - 5 All of the following:
 - 5.1 Ambrisentan is to be used as PAH dual therapy; and
 - 5.2 Either:
 - 5.2.1 Patient has tried a PAH monotherapy (sildenafil or bosentan) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; or
 - 5.2.2 Patient has tried PAH dual therapy including bosentan and has experienced intolerable side effects on bosentan; and
 - 5.3 Both:
 - 5.3.1 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy; and
 - 5.3.2 Patient has an absolute or relative contraindication to bosentan (eg due to current use of a combined oral contraceptive or liver disease);
 - 5.2 Any of the following:
 - 5.2.1 Patient has tried bosentan (either as PAH monotherapy, or PAH dual therapy with sildenafil) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; or
 - 5.2.2 Patient has experienced intolerable side effects on bosentan; or
 - 5.2.3 Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); and
 - 5.3 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

INFECTIONS

89	CEFUROXIME (delay PSS and delist date)			
	Inj 750 mg vial – 5% DV May Jun-24 to 2026	8.16	10	Cefuroxime Devatis
		8.59		Cefuroxime-AFT
	Inj 1.5 g vial – 5% DV May Jun-24 to 2026	13.01	10	Cefuroxime Devatis
		13.69		Cefuroxime-AFT
	Note – Cefuroxime-AFT inj 750 mg and 1.5 g vial to be delisted from 1 June May 2024			
93	CIPROFLOXACIN (new listing)			
	→ Tab 500 mg	4.25	10	Ciprofloxacin - Torrent
104	DOLUTEGRAVIR WITH LAMIVUDINE (new listing)			
	→ Tab 50 mg with lamivudine 300 mg	1,090.00	30	Dovato

NERVOUS SYSTEM

126	MIRTAZAPINE (new listing)			
	Tab 30 mg – 1% DV Jan-22 to 2024	2.60	30	Noumed
	Tab 45 mg – 1% DV Jan-22 to 2024	3.45	30	Noumed
131	HYOSCINE HYDROBROMIDE (new listing)			
	→ Patch 1 mg per 72 hours	88.50	10	Scopolamine – Mylan
	Note – new Pharmacode listing, 2666391			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

152 NIRAPARIB (new listing)

→ Cap 100 mg	8,929.84	56	Zejula
	13,393.50	84	Zejula

Initiation

Reassessment required after 6 months

All of the following:

- 1 Patient has advanced high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 Patient has received at least one line** of treatment with platinum-based chemotherapy; and
- 3 Patient has experienced a partial or complete response to the preceding treatment with platinum-based chemotherapy; and
- 4 Patient has not previously received funded treatment with a PARP inhibitor; and
- 5 Either:
 - 5.1 Treatment will be commenced within 12 weeks of the patient's last dose of the preceding platinum-based regimen; or
 - 5.2 Patient commenced treatment with niraparib prior to 1 May 2024; and
- 6 Treatment to be administered as maintenance treatment; and
- 7 Treatment not to be administered in combination with other chemotherapy.

Continuation

Reassessment required after 6 months

All of the following:

- 1 No evidence of progressive disease; and
- 2 Treatment to be administered as maintenance treatment; and
- 3 Treatment not to be administered in combination with other chemotherapy; and
- 4 Either:
 - 4.1 Treatment with niraparib to cease after a total duration of 36 months from commencement; or
 - 4.2 Treatment with niraparib is being used in the second-line or later maintenance setting.

Notes:

* "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

158 ERLOTINIB (↓ price and addition of PSS)

→ Tab 100 mg – 5% DV Oct-24 to 2027	280.84	30	Alchemy
→ Tab 150 mg – 5% DV Oct-24 to 2027	484.24	30	Alchemy

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

204	MEPOLIZUMAB (amended restriction criteria – new criteria shown only)			
	→ Inj 100 mg prefilled pen	1,638.00	1	Nucala
	→ Inj 100 mg vial	1,638.00	1	Nucala

Initiation – Eosinophilic granulomatosis with polyangiitis

Re-assessment required after 12 months

All of the following:

- 1 The patient has eosinophilic granulomatosis with polyangiitis; and
- 2 The patient has trialled and not received adequate benefit from at least one of the following for at least three months (unless contraindicated to all): azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate, or rituximab; and
- 3 Either:

3.1 The patient has trialled prednisone for a minimum of three months and is unable to maintain disease control at doses below 7.5 mg per day; or

3.2 Corticosteroids are contraindicated.

Continuation – Eosinophilic granulomatosis with polyangiitis

Re-assessment required after 12 months

Patient has no evidence of clinical disease progression.

224	TOCILIZUMAB (amended restriction criteria – amended criteria shown only)			
	→ Inj 20 mg per ml, 4 ml vial	220.00	1	Actemra
	→ Inj 20 mg per ml, 10 ml vial	550.00	1	Actemra
	→ Inj 20 mg per ml, 20 ml vial	1,100.00	1	Actemra

Initiation – cytokine release syndrome

Therapy limited to 3 doses

Either:

1 All of the following:

- 1.1 The patient is enrolled in the Children’s Oncology Group AALL1731 trial; and
- 1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
- 1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or

2 All of the following:

- 2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial programme; and
- 2.2 The patient has developed CRS or **Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)** following CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
- 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS or **ICANS** and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47–62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

245 Inhaled Corticosteroid with Long-Acting Muscarinic Antagonist and Beta Agonist (new subtherapeutic heading and new listing)
FLUTICASONE FUROATE WITH UMECLIDINIUM AND VILANTEROL

→ Powder for inhalation fluticasone furoate 100 mcg with
umeclidinium 62.5 mcg and vilanterol 25 mcg..... 104.24 30 dose Trelegy Ellipta

Initiation

Both:

1 Patient has a diagnosis of COPD confirmed by spirometry or spirometry has been attempted and technically acceptable results are not possible; and

2 Either:

2.1 Both:

2.1.1 Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA); and

2.1.2 Any of the following:

Clinical criteria:

2.1.2.1 Patient has a COPD Assessment Test (CAT) score greater than 10; or

2.1.2.2 Patient has had 2 or more exacerbations in the previous 12 months; or

2.1.2.3 Patient has had one exacerbation requiring hospitalisation in the previous 12 months; or

2.1.2.4 Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months; or

2.2 Patient is currently receiving multiple inhaler triple therapy (inhaled corticosteroid with long acting muscarinic antagonist and long acting beta-2 agonist – ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to commencing multiple inhaler triple therapy.

249 THEOPHYLLINE († price)

Tab long-acting 250 mg..... 24.90 100 Nuelin-SR

Oral liq 80 mg per 15 ml..... 17.95 500 ml Nuelin

VARIOUS

261 POVIDONE-IODINE († price)

Soln 10%..... 6.99 500 ml Riodine

SPECIAL FOODS

270 CARBOHYDRATE SUPPLEMENT (delisting any brand)

→ Powder 95 g carbohydrate per 100 g, 368 g can

→ Powder 96 g carbohydrate per 100 g, 400 g can

e.g. Polycal

Note – Powder 95 g carbohydrate per 100 g, 368 g can and e.g. Polycal to be delisted from 1 May 2024

270 CARBOHYDRATE SUPPLEMENT (new listing)

→ Powder 96 g carbohydrate per 100 g, can..... 6.72 400 g Polycal

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

270	LONG-CHAIN TRIGLYCERIDE SUPPLEMENT (delisting any brand) → Liquid 50 g fat per 100 ml, 200 ml bottle → Liquid 50 g fat per 100 ml, 500 ml bottle Note – e.g. Calogen, 200 ml bottle and 500 ml bottle to be delisted from 1 May 2024			<i>e.g. Calogen</i> <i>e.g. Calogen</i>
270	LONG-CHAIN TRIGLYCERIDE SUPPLEMENT (new listing) → Liquid 50 g fat per 100 ml, bottle	15.38	200 ml	Calogen (neutral)
		38.44	500 ml	Calogen (strawberry) Calogen (neutral)
271	MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT (delisting any brand) → Liquid 50 g fat per 100 ml, 250 ml bottle → Liquid 95 g fat per 100 ml, 500 ml bottle Note – e.g. Liquigen and MCT Oil to be delisted from 1 May 2024			<i>e.g. Liquigen</i> <i>e.g. MCT Oil</i>
272	MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT (new listing) → Liquid 50 g fat per 100 ml, 250 ml bottle.....	143.65	4	Liquigen
	→ Liquid 95 g fat per 100 ml, bottle	37.50	500 ml	MCT Oil
271	PROTEIN SUPPLEMENT (delisting any brand) → Powder 89 g protein, < 1.5 g carbohydrate and 2 g fat per 100 g, 225 g can Note – e.g. Protifar to be delisted from 1 May 2024			<i>e.g. Protifar</i>
272	PROTEIN SUPPLEMENT (new listing) → Powder 89 g protein, less than 1.5 g carbohydrate and 2 g fat per 100 g, can.....	13.82	225 g	Protifar
271	HUMAN BREAST MILK FORTIFIER (amended chemical name and delisting any brand) Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet Note – e.g. S26 Human Milk Fortifier and Nutricia Breast Milk Fortifier to be delisted from 1 May 2024			<i>e.g. FM 85</i> <i>e.g. S26 Human Milk Fortifier</i> <i>e.g. Nutricia Breast Milk Fortifier</i>
272	HUMAN MILK FORTIFIER (new listing) Powder 0.325 g protein, 0.37 g carbohydrate and 0.175 g fat per 1g sachet.....	33.48	50	Human Milk Fortifier
271	CARBOHYDRATE AND FAT SUPPLEMENT (delisting any brand) → Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can Note – Super Soluble Duocal to be delisted from 1 May 2024			<i>e.g. Super Soluble Duocal</i>
272	CARBOHYDRATE AND FAT SUPPLEMENT (new listing) → Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, can.....	71.77	400 g	Duocal Super Soluble Powder
272	AMINO ACID FORMULA (WITHOUT LYSINE) (delisting) → Powder, 15 g protein, 3.4 g carbohydrate, 0.05 g fat per 25 g sachet	1,048.95	30	GA Express 15
	Note – GA Express 15 to be delisted from 1 May 2024			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 May 2024 (continued)				
272	CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN (delisting any brand) Powder			<i>e.g. Feed Thickeners Karicare Aptamil</i>
	Note – e.g. Feed Thickeners Karicare Aptamil to be delisted from 1 May 2024			
273	CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN (new listing) Powder.....	24.00	380 g	Aptamil Feed Thickeners
273	MAIZE STARCH (delisting any brand) Powder			<i>e.g. Resource Thicken Up; Nutilis</i>
	Note – e.g. Resource Thicken Up; Nutilis to be delisted from 1 May 2024			
273	MAIZE STARCH (new listing) Powder.....	8.29	300 g	Nutilis
277	LOW-GI ORAL FEED 1 KCAL/ML (delisting any brand) → Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle			<i>e.g. Diasip</i>
	Note – e.g. Diasip to be delisted from 1 July 2024			
277	GLYCEROL TRIOLEATE (new listing) → Liquid, bottle.....	131.80	500 ml	GTO Oil
278	AMINO ACID ORAL FEED 0.8 KCAL/ML (delisting any brand) → Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton			<i>e.g. Elemental 028 Extra</i>
	Note – e.g. Elemental 028 Extra to be delisted from 1 May 2024			
279	AMINO ACID ORAL FEED 0.8 KCAL/ML (new listing) → Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton	179.46	18	Elemental 028 Extra (grapefruit) Elemental 028 Extra (summer fruits) Elemental 028 Extra (pineapple and orange)
278	FAT-MODIFIED FEED (delisting any brand) → Powder 12.8 g protein, 68.6 g carbohydrate and 12.9 g fat per 100 g, 400 g can			<i>e.g. Monogen</i>
	Note – e.g. Monogen to be delisted from 1 May 2024			
279	FAT-MODIFIED FEED (new listing) → Powder 12.8 g protein, 68.6 g carbohydrate and 12.9 g fat per 100 g, can.....	62.90	400 g	Monogen
279	PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML (new listing) → Liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, bottle.....	7.47	500 ml	Nutrison Advanced Peptisorb
279	HEPATIC ORAL FEED (↑ price) → Powder 12 g protein, 56 g carbohydrate and 22 g fat per 100 g, can.....	93.97	400 g	Heparon Junior

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

279	HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML (delisting any brand) → Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bottle Note – e.g. Nutrison Protein Plus to be delisted from 1 May 2024			<i>e.g. Nutrison Protein Plus</i>
280	HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML (new listing) → Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, bottle.....	12.00	1,000 ml	Nutrison Protein Plus
280	HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML (delisting any brand) → Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle Note – e.g. Nutrison Protein Plus Multi Fibre to be delisted from 1 May 2024			<i>e.g. Nutrison Protein Plus Multi Fibre</i>
281	HIGH PROTEIN ENTERAL FEED 1.26 KCAL/ML (new listing) → Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, bottle.....	12.54	1,000 ml	Nutrison Protein Plus Multi Fibre
280	ENTERAL FEED 2 KCAL/ML (↑ price) → Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle.....	6.82	500 ml	Nutrison Concentrated
281	AMINO ACID FORMULA (delisting any brand) → Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g can → Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can Note – e.g. Neocate SYNEO unflavoured and Neocate Junior Unflavoured to be delisted from 1 May 2024			<i>e.g. Neocate SYNEO unflavoured e.g. Neocate Junior Unflavoured</i>
282	AMINO ACID FORMULA (new listing) → Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, can..... → Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, can..... Note – Neocate SYNEO, new Pharmacode listings 2587955 and 2555271.	55.61 55.61	400 g 400 g	Neocate SYNEO Neocate Junior Unflavoured
281	HIGH PROTEIN ENTERAL FEED 1.26 KCAL/ML (↑ price) → Liquid 10 g protein, 10.4 g carbohydrate and 4.9 g fat per 100 ml, bottle.....	8.67	500 ml	Nutrison Protein Intense
282	AMINO ACID FORMULA (↑ price) → Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can..... → Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per 100 g, can.....	55.61 55.61	400 g 400 g	Neocate Gold (Unflavoured) Neocate Junior Vanilla
282	ENTERAL LIQUID PEPTIDE FORMULA (↑ price) → Liquid 4.2 g protein, 18.6 g carbohydrate and 6.58 g fat per 100 ml	18.66	500 ml	Nutrini Peptisorb Energy

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 May 2024 (continued)				
283	EXTENSIVELY HYDROLYSED FORMULA († price) → Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can.....	36.20	900 g	Allerpro Syneo 1
	→ Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can.....	36.20	900 g	Allerpro Syneo 2
283	LOW-CALCIUM FORMULA (delisting any brand) Powder 14.6 g protein, 55.2 g carbohydrate and 25.8 g fat per 100 g, 400 g can Note – e.g. Locasol to be delisted from 1 May 2024			<i>e.g. Locasol</i>
284	LOW-CALCIUM FORMULA (new listing) Powder 14.6 g protein, 55.2 g carbohydrate and 25.8 g fat per 100 g, can.....	46.18	400 g	Locasol
283	EXTENSIVELY HYDROLYSED FORMULA (new listing) → Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, can.....	18.10	450 g	Pepti-Junior
283	EXTENSIVELY HYDROLYSED FORMULA (delisting any brand) → Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can Note – e.g. Pepti-Junior to be delisted from 1 May 2024			<i>e.g. Pepti-Junior</i>
284	PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML († price) → Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, bottle.....	2.80	125 ml	Infatrini
284	PAEDIATRIC ENTERAL FEED 1 KCAL/ML (delisting any brand) → Liquid 2.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bottle → Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bottle Note – e.g. Nutrini RTH and Nutrini Energy RTH to be delisted from 1 May 2024			<i>e.g. Nutrini RTH</i> <i>e.g. Nutrini Energy RTH</i>
285	PAEDIATRIC ENTERAL FEED 1 KCAL/ML (new listing) → Liquid 2.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, bottle.....	4.69	500 ml	Nutrini RTH
285	PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML (new listing) → Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, bottle.....	7.46	500 ml	Nutrini Energy RTH
285	HIGH FAT FORMULA († price) → Powder 14.3 g protein, 2.8 g carbohydrate and 69.2 g fat per 100 g, can..... → Powder 15.4 g protein, 7.2 g carbohydrate and 68.6 g fat per 100 g, can.....	36.92 36.92	300 g 300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla) Ketocal 3:1 (Unflavoured)
285	PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML (new listing) → Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag.....	6.27	500 ml	Nutrini Low Energy Multifibre RTH
	Note – new Pharmacode listing, 2565234. Nutrini Low Energy Multifibre RTH, Pharmacode 2400421, to be delisted from 1 May 2024			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

285	PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML (↑ price) → Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bottle.....	7.14	500 ml	Nutrini Energy Multi Fibre
285	PAEDIATRIC ORAL FEED 1.5 KCAL/ML (delisting any brand) → Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle → Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle Note – e.g. Fortini and Fortini Multifibre to be delisted from 1 May 2024			e.g. Fortini e.g. Fortini Multifibre
286	PAEDIATRIC ORAL FEED 1.5 KCAL/ML (new listing) → Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, bottle	1.90	200 ml	Fortini (Strawberry) Fortini (Vanilla)
	→ Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, bottle.....	1.90	200 ml	Fortini Multi Fibre (Unflavoured) Fortini Multi Fibre (Chocolate) Fortini Multi Fibre (Strawberry) Fortini Multi Fibre (Vanilla)
285	LOW ELECTROLYTE ORAL FEED (delisting any brand) → Powder 7.5 g protein, 57.6 g carbohydrate and 25.9 g fat per 100 g, 400 g can Note – e.g. Kindergen to be delisted from 1 May 2024			e.g. Kindergen
286	LOW ELECTROLYTE ORAL FEED (new listing) → Powder 7.5 g protein, 57.6 g carbohydrate and 25.9 g fat per 100 g, can.....	64.26	400 g	Kindergen
285	LOW ELECTROLYTE ORAL FEED 2 KCAL/ML (delisting any brand) → Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton Note – e.g. Renilon 7.5 to be delisted from 1 May 2024			e.g. Renilon 7.5
286	LOW ELECTROLYTE ORAL FEED 2 KCAL/ML (new listing) → Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton.....	13.72	4	Renilon 7.5 (apricot) Renilon 7.5 (caramel)
287	PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML (↑ price) → Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle	8.64	4	preOp
287	ENTERAL FEED 1.5 KCAL/ML (↑ price) → Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bottle.....	9.00	1,000 ml	Nutrison Energy

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2024 (continued)

286	ENTERAL FEED 1.5 KCAL/ML (delisting any brand) → Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle Note – e.g. Nutrison Energy Multi Fibre to be delisted from 1 May 2024			<i>e.g. Nutrison Energy Multi Fibre</i>
287	ENTERAL FEED 1.5 KCAL/ML (new listing) → Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, bottle.....	8.68	1,000 ml	Nutrison Energy Multi Fibre
287	ENTERAL FEED 1 KCAL/ML (delisting any brand) → Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bottle → Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bottle Note – e.g. Nutrison Multi Fibre, Nutrison Low Sodium; NutrisonStdRTH to be delisted from 1 May 2024			<i>e.g. Nutrison Multi Fibre</i> <i>e.g. Nutrison Low Sodium; NutrisonStdRTH</i>
288	ENTERAL FEED 1 KCAL/ML (new listing) → Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, bottle.....	7.21	1000 ml	Nutrison Multi Fibre
288	ENTERAL FEED 1 KCAL/ML (new listing) → Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, bottle.....	6.90	1,000 ml	Nutrison RTH
288	ENTERAL FEED WITH FIBRE 0.83 KCAL/ML (↑ price) → Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, bottle.....	9.05	1,000 ml	Nutrison 800 Complete Multi Fibre
288	ORAL FEED 1.5 KCAL/ML (delisting any brand) → Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle → Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle → Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle Note – e.g. Fortijuice to be delisted from 1 May 2024 and e.g. Fortisip and e.g. Fortisip Multi Fibre to be delisted from 1 July 2024			<i>e.g. Fortijuice</i> <i>e.g. Fortisip</i> <i>e.g. Fortisip Multi Fibre</i>
289	ORAL FEED 1.5 KCAL/ML (new listing) → Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, bottle.....	3.30	200 ml	Fortijuice (Apple) Fortijuice (Orange) Fortijuice (Strawberry)

Index

Pharmaceuticals and brands

A	
Actemra.....	14
Allerpro Syneo 1.....	19
Allerpro Syneo 2.....	19
AMBRISENTAN.....	11
Ambrisentan Viatrix.....	11
AMINO ACID FORMULA.....	18
AMINO ACID FORMULA (WITHOUT LYSINE).....	16
AMINO ACID ORAL FEED 0.8 KCAL/ML.....	17
Aptamil Feed Thickener.....	17
B	
BREAST MILK FORTIFIER.....	16
C	
Calogen.....	16
Calogen (neutral).....	16
Calogen (strawberry).....	16
CARBOHYDRATE AND FAT SUPPLEMENT.....	16
CARBOHYDRATE SUPPLEMENT.....	15
CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN.....	17
CEFUROXIME.....	12
Cefuroxime-AFT.....	12
Cefuroxime Devatis.....	12
CIPROFLOXACIN.....	12
Ciprofloxacin - Torrent.....	12
D	
Diasip.....	17
DOLUTEGRAVIR WITH LAMIVUDINE.....	12
Dovato.....	12
DULAGLUTIDE.....	8
Duocal Super Soluble Powder.....	16
E	
Elemental 028 Extra.....	17
Elemental 028 Extra (grapefruit).....	17
Elemental 028 Extra (pineapple and orange).....	17
Elemental 028 Extra (summer fruits).....	17
ENTERAL FEED 1.5 KCAL/ML.....	20, 21
ENTERAL FEED 1 KCAL/ML.....	21
ENTERAL FEED 2 KCAL/ML.....	18
ENTERAL FEED WITH FIBRE 0.83 KCAL/ML.....	21
ENTERAL LIQUID PEPTIDE FORMULA.....	18
ERLOTINIB.....	13
EXTENSIVELY HYDROLYSED FORMULA.....	19
F	
FAT-MODIFIED FEED.....	17
Feed Thickener Karicare Aptamil.....	17
FLECAINIDE ACETATE.....	10
FLUTICASON FUROATE WITH UMECLIDINIUM AND VILANTEROL.....	15
FM 85.....	16
Fortijuice.....	21
Fortijuice (Apple).....	21
Fortijuice (Orange).....	21
Fortijuice (Strawberry).....	21
Fortini.....	20
Fortini Multifibre.....	20
Fortini Multi Fibre (Chocolate).....	20
Fortini Multi Fibre (Strawberry).....	20
Fortini Multi Fibre (Unflavoured).....	20
Fortini Multi Fibre (Vanilla).....	20
Fortini (Strawberry).....	20
Fortini (Vanilla).....	20
Fortisip.....	21
Fortisip Multi Fibre.....	21
G	
GA Express 15.....	16
GLYCEROL TRIOLEATE.....	17
GTO Oil.....	17
H	
Heparon Junior.....	17
HEPATIC ORAL FEED.....	17
HIGH FAT FORMULA.....	19
HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML.....	18
HIGH PROTEIN ENTERAL FEED 1.26 KCAL/ML.....	18
HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML.....	18
Human Milk Fortifier.....	16
HUMAN MILK FORTIFIER.....	16
HYOSCINE HYDROBROMIDE.....	12
I	
Infatrini.....	19
K	
Ketocal 3:1 (Unflavoured).....	19
Ketocal 4:1 (Unflavoured).....	19
Ketocal 4:1 (Vanilla).....	19
Kindergen.....	20
L	
Liquigen.....	16
LIRAGLUTIDE.....	9
Locasol.....	19
LONG-CHAIN TRIGLYCERIDE SUPPLEMENT.....	16
LOW-CALCIUM FORMULA.....	19
LOW ELECTROLYTE ORAL FEED.....	20
LOW ELECTROLYTE ORAL FEED 2 KCAL/ML.....	20
LOW-GI ORAL FEED 1 KCAL/ML.....	17
M	
MAIZE STARCH.....	17
MCT Oil.....	16
MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT.....	16
MEPOLIZUMAB.....	14
MIRTAZAPINE.....	12

Index

Pharmaceuticals and brands

Monogen	17	PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML	19
MULTIVITAMINS	10	PAEDIATRIC ORAL FEED 1.5 KCAL/ML	20
N		Paediatric Seravit	10
Neocate Gold (Unflavoured).....	18	PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML	17
Neocate Junior Unflavoured.....	18	Pepti-Junior	19
Neocate Junior Vanilla	18	Polycal.....	15
Neocate SYNEO	18	POVIDONE-IODINE	15
Neocate SYNEO unflavoured.....	18	preOp	20
NIRAPARIB	13	PREOPERATIVE CARBOHYDRATE FEED	
Nucala	14	0.5 KCAL/ML	20
Nuelin	15	PROTEIN SUPPLEMENT	16
Nuelin-SR	15	Protifar.....	16
Nutilis	17	R	
Nutricia Breast Milk Fortifer.....	16	Renilon 7.5	20
Nutrini Energy Multi Fibre.....	20	Renilon 7.5 (apricot)	20
Nutrini Energy RTH.....	19	Renilon 7.5 (caramel).....	20
Nutrini Low Energy Multifibre RTH	19	Resource Thicken Up; Nutilis.....	17
Nutrini Peptisorb Energy.....	18	Riodine	15
Nutrini RTH	19	S	
Nutrison 800 Complete Multi Fibre.....	21	S26 Human Milk Fortifier	16
Nutrison Advanced Peptisorb	17	Scopolamine – Mylan.....	12
Nutrison Concentrated.....	18	Super Soluble Duocal	16
Nutrison Energy	20	T	
Nutrison Energy Multi Fibre.....	21	Tambocor	10
Nutrison Low Sodium; NutrisonStdRTH	21	THEOPHYLLINE.....	15
Nutrison Multi Fibre	21	TOCILIZUMAB	14
Nutrison Protein Intense	18	Trelegy Ellipta	15
Nutrison Protein Plus.....	18	TRIENTINE	10
Nutrison Protein Plus Multi Fibre.....	18	TRIENTINE DIHYDROCHLORIDE	10
Nutrison RTH	21	Trientine Waymade	10
O		Trulicity.....	8
ORAL FEED 1.5 KCAL/ML	21	V	
P		Victoza.....	9
PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML	19	Z	
PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML	19, 20	Zejula.....	13
PAEDIATRIC ENTERAL FEED 1 KCAL/ML	19		

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

